
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023.**

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to**

Commission File Number: 000-52684

Progressive Care Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

400 Ansin Blvd., Suite A, Hallandale Beach, FL
(Address of principal executive offices)

32-0186005

(I.R.S. Employer
Identification No.)

33009
(Zip Code)

(305) 760-2053

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class

N/A

Trading Symbol

N/A

Name of each exchange on which registered

N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer

Accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The number of shares of the registrant's common stock outstanding as of November 8, 2023 was 6,222,781.

**PROGRESSIVE CARE INC. AND SUBSIDIARIES
INDEX**

	<u>Page</u>
PART I. FINANCIAL INFORMATION	
Item 1. Condensed Consolidated Financial Statements (Unaudited)	F-1
Condensed Consolidated Balance Sheets	F-1
Condensed Consolidated Statements of Operations	F-2
Condensed Consolidated Statements of Stockholders' Equity	F-3
Condensed Consolidated Statements of Cash Flows	F-4
Notes to the Condensed Consolidated Financial Statements	F-5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3. Quantitative and Qualitative Disclosures about Market Risk	9
Item 4. Controls and Procedures	9
PART II. OTHER INFORMATION	
Item 1. Legal Proceedings	10
Item 1A. Risk Factors	10
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities	10
Item 3. Defaults Upon Senior Securities	11
Item 4. Mine Safety Disclosures	11
Item 5. Other Information	11
Item 6. Exhibits	12
Signatures	13

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report and other documents that we file with the Securities and Exchange Commission contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management's assumptions. Statements that are not historical facts are forward-looking statements, including forward-looking information concerning pharmacy sales trends, prescription margins, number and location of new store openings, outcomes of litigation, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, acquisition synergies, regulatory approvals, and competitive strengths. Words such as "expect," "outlook," "forecast," "would," "could," "should," "project," "intend," "plan," "continue," "sustain," "on track," "believe," "seek," "estimate," "anticipate," "may," "assume," and variations of such words and similar expressions are often used to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those described in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission ("SEC") on March 30, 2023 ("2022 Form 10-K"), this quarterly report on Form 10-Q for the three months ended September 30, 2023, and our other reports that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after the date they are made, whether as a result of new information, future events, changes in assumptions or otherwise.

PART I - FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

PROGRESSIVE CARE INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)

	Successor	Predecessor
	September 30, 2023	December 31, 2022
Assets		
Current Assets		
Cash	\$ 7,014,971	\$ 6,742,876
Accounts receivable – trade, net	7,247,809	3,671,786
Receivables - other, net	2,945,327	2,004,805
Inventory, net	3,005,083	713,284
Prepaid expenses	257,957	245,983
Total Current Assets	20,471,147	13,378,734
Property and equipment, net	3,167,520	2,582,753
Other Assets		
Goodwill	3,144,000	1,387,860
Intangible assets, net	14,085,497	126,696
Operating right-of-use assets, net	328,887	446,180
Finance right-of-use assets, net	28,807	53,814
Deposits	39,137	38,637
Total Other Assets	17,626,328	2,053,187
Total Assets	\$ 41,264,995	\$ 18,014,674
Liabilities and Stockholders' Equity		
Current Liabilities		
Accounts payable and accrued liabilities	\$ 12,376,854	\$ 7,384,336
Notes payable	145,736	226,931
Operating lease liabilities	170,079	200,314
Finance lease liabilities	20,691	33,616
Total Current Liabilities	12,713,360	7,845,197
Long-term Liabilities		
Notes payable, net of current portion	1,139,297	2,248,626
Operating lease liabilities, net of current portion	187,886	278,602
Finance lease liabilities, net of current portion	9,897	24,198
Total Liabilities	14,050,440	10,396,623
Commitments and Contingencies	—	—
Stockholders' Equity		
Preferred Stock, Series B (\$0.001 par value, 100,000 shares designated; 3,000 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively)	3	3
Common stock (\$0.0001 par value, 100,000,000 shares authorized; 6,189,448 and 3,347,440 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively)	67,231	66,947
Additional paid-in capital	48,263,547	22,525,214
Accumulated deficit	(21,116,226)	(14,974,113)
Total Stockholders' Equity	27,214,555	7,618,051
Total Liabilities and Stockholders' Equity	\$ 41,264,995	\$ 18,014,674

See accompanying notes to the unaudited condensed consolidated financial statements.

PROGRESSIVE CARE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)

	Successor	Predecessor		
	Three Months Ended September 30, 2023	Six Months Ended June 30, 2023	Three Months Ended September 30, 2022	Nine Months Ended September 30, 2022
Sales of products, net	\$ 9,858,037	\$ 19,193,310	\$ 8,952,841	\$ 27,751,802
Revenues from services	2,501,413	3,754,719	1,191,040	2,416,658
Revenues, net	<u>12,359,450</u>	<u>22,948,029</u>	<u>10,143,881</u>	<u>30,168,460</u>
Costs of products	8,507,351	16,132,673	7,926,442	23,402,593
Costs of services	71,536	109,825	55,354	192,823
Costs of revenue	<u>8,578,887</u>	<u>16,242,498</u>	<u>7,981,796</u>	<u>23,595,416</u>
Gross profit	<u>3,780,563</u>	<u>6,705,531</u>	<u>2,162,085</u>	<u>6,573,044</u>
Operating expenses				
Salaries and wages	1,919,517	3,299,607	1,301,503	4,028,139
Professional fees	242,854	1,048,272	536,811	827,351
Depreciation and amortization	707,554	136,686	49,493	145,691
Selling, general, and administrative	2,268,708	1,582,999	2,152,345	3,782,756
Total operating expenses	<u>5,138,633</u>	<u>6,067,564</u>	<u>4,040,152</u>	<u>8,783,937</u>
(Loss) income from operations	<u>(1,358,070)</u>	<u>637,967</u>	<u>(1,878,067)</u>	<u>(2,210,893)</u>
Other income (loss)				
Change in fair value of derivative liabilities	—	—	(7,894,100)	(9,067,500)
Gain on debt extinguishment	—	—	1,015,401	953,228
Grant revenue	—	—	2,079,297	2,079,297
Debt conversion expense	—	(5,205,609)	—	—
Other finance costs	—	—	(418)	(147,622)
Abandoned offering costs	—	—	(635,545)	(635,545)
Day one loss on issuance of units	—	—	(1,026,155)	(1,026,155)
Day one loss on debt modification	—	—	(523,526)	(523,526)
Gain on sale or disposal of property and equipment	—	2,500	—	11,562
Interest income	21,588	12,417	8,378	8,378
Interest expense	(38,266)	(214,640)	(107,893)	(645,183)
Total other loss	<u>(16,678)</u>	<u>(5,405,332)</u>	<u>(7,084,561)</u>	<u>(8,993,066)</u>
Loss before income taxes	<u>(1,374,748)</u>	<u>(4,767,365)</u>	<u>(8,962,628)</u>	<u>(11,203,959)</u>
Provision for income taxes	—	—	—	(866)
Net loss	<u>(1,374,748)</u>	<u>(4,767,365)</u>	<u>(8,962,628)</u>	<u>(11,204,825)</u>
Series A Preferred Stock dividend associated with induced conversion	—	—	(541,278)	(541,278)
Net loss attributable to common shareholders	<u>\$ (1,374,748)</u>	<u>\$ (4,767,365)</u>	<u>\$ (9,503,906)</u>	<u>\$ (11,746,103)</u>
Basic and diluted weighted average loss per common share	<u>\$ (0.22)</u>	<u>\$ (1.22)</u>	<u>\$ (3.29)</u>	<u>\$ (4.21)</u>
Weighted average number of common shares outstanding during the year – basic and diluted	<u>6,173,444</u>	<u>3,895,532</u>	<u>2,886,408</u>	<u>2,786,849</u>

See accompanying notes to the unaudited condensed consolidated financial statements.

PROGRESSIVE CARE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)

	Preferred Stock, Series B		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	\$0.001 Par Value		\$0.0001 Par Value				
	Shares	Amount	Shares	Amount			
Balance at December 31, 2022 (Predecessor)	3,000	\$ 3	3,347,440	\$ 66,947	\$ 22,525,214	\$ (14,974,113)	\$ 7,618,051
Stock-based compensation	—	—	10,861	1	50,001	—	50,002
Net loss for the three months ended March 31, 2023	—	—	—	—	—	(130,339)	(130,339)
Balance at March 31, 2023	3,000	3	3,358,301	66,948	22,575,215	(15,104,452)	7,537,714
Stock-based compensation	—	—	62,353	6	199,594	—	199,600
Issuance of common stock for PIPE transaction	—	—	455,000	46	999,954	—	1,000,000
Cost associated with issuance of common stock for PIPE transaction	—	—	—	—	(120,000)	—	(120,000)
Issuance of common stock and common stock purchase warrants for debt conversion	—	—	1,312,379	131	6,400,332	—	6,400,463
Net loss for the three months ended June 30, 2023	—	—	—	—	—	(4,637,026)	(4,637,026)
Balance at June 30, 2023 (Predecessor)	3,000	3	5,188,033	67,131	30,055,095	(19,741,478)	10,380,751
Issuance of common stock for warrants exercised on July 1, 2023	—	—	974,310	97	505,903	—	506,000
Balance at July 1, 2023 (Successor)	3,000	3	6,162,343	67,228	47,096,712	(19,741,478)	27,422,465
Stock-based compensation	—	—	27,105	3	1,201,835	—	1,201,838
Cost associated with issuance of common stock for PIPE transaction	—	—	—	—	(35,000)	—	(35,000)
Net loss for the three months ended September 30, 2023	—	—	—	—	—	(1,374,748)	(1,374,748)
Balance at September 30, 2023 (Successor)	3,000	3	6,189,448	67,231	48,263,547	(21,116,226)	27,214,555

	Predecessor								
	Preferred Stock, Series A		Preferred Stock, Series B		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	\$0.001 Par Value		\$0.001 Par Value		\$0.0001 Par Value				
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance December 31, 2021	51	\$ —	—	\$ —	2,724,422	\$ 54,487	\$ 8,862,050	\$ (8,528,937)	\$ 387,600
Issuance of common stock for services	—	—	—	—	3,094	62	20,938	—	21,000
Stock-based compensation	—	—	—	—	17,297	348	104,652	—	105,000
Net loss for the three months ended March 31, 2022	—	—	—	—	—	—	—	(1,361,476)	(1,361,476)
Balance March 31, 2022	51	—	—	—	2,744,813	54,897	8,987,640	(9,890,413)	(847,876)
Net loss for the three months ended June 30, 2022	—	—	—	—	—	—	—	(880,721)	(880,721)
Balance June 30, 2022	51	—	—	—	2,744,813	54,897	8,987,640	(10,771,134)	(1,728,597)
Issuance of common stock for services	—	—	—	—	138,378	2,768	655,914	—	658,682
Stock-based compensation	—	—	—	—	28,300	566	159,434	—	160,000
Issuance of Common Stock for Debt Modification Agreement	—	—	—	—	105,000	2,100	459,900	—	462,000
Issuance of common stock in exchange for redemption and cancellation of Series A Preferred Stock	(51)	—	—	—	127,564	2,551	538,727	—	541,278
Series A Preferred Stock dividend associated with induced conversion	—	—	—	—	—	—	—	(541,278)	(541,278)
Issuance of Series B Preferred Stock from securities purchase agreement	—	—	3,000	—	—	—	—	—	—
Stock Options granted during the period	—	—	—	—	—	—	482,524	—	482,524
Net loss for the three months ended September 30, 2022	—	—	—	—	—	—	—	(8,962,628)	(8,962,628)
Balance September 30, 2022	—	\$ —	3,000	\$ —	3,144,055	\$ 62,882	\$ 11,284,139	\$ (20,275,040)	\$ (8,928,019)

See accompanying notes to the unaudited condensed consolidated financial statements.

PROGRESSIVE CARE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	<u>Successor</u>	<u>Predecessor</u>	
	<u>Three Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2023</u>	<u>Six Months</u> <u>Ended June</u> <u>30,</u> <u>2023</u>	<u>Nine Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2022</u>
Cash flows from operating activities:			
Net loss	\$ (1,374,748)	\$ (4,767,365)	\$ (11,746,103)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:			
Depreciation	64,715	95,646	96,772
Change in provision for doubtful accounts	12,000	21,100	(20,200)
Stock-based compensation	1,201,838	249,602	1,421,690
Amortization of debt issuance costs and debt discounts	—	128,211	317,923
Gain on debt extinguishment	—	—	(953,228)
Debt conversion expense	—	5,205,609	—
Other financing costs	—	—	147,622
Series A Preferred Stock dividend associated with induced conversion	—	—	541,278
Day one loss on issuance of units	—	—	1,026,155
Day one loss on debt modification	—	—	523,526
Amortization of right-of-use assets - finance leases	8,336	16,672	25,008
Amortization of right-of-use assets - operating leases	39,383	77,909	111,533
Change in fair value of derivative liability	—	—	9,067,500
Change in accrued interest on notes payable	—	46,552	285,466
Amortization of intangible assets	634,503	24,369	23,911
Gain on sale or disposal of property and equipment	—	(2,500)	(11,562)
Changes in operating assets and liabilities:			
Accounts receivable	(3,726,973)	(1,099,995)	(442,038)
Grant receivable	—	277,322	(1,655,862)
Inventory	(1,374,202)	(917,597)	252,206
Prepaid expenses	(37,643)	25,669	715,389
Deposits	—	(500)	—
Accounts payable and accrued liabilities	4,334,580	850,660	1,366,335
Operating lease liabilities	(41,617)	(81,155)	(94,133)
Net cash (used in) provided by operating activities	(259,828)	150,209	999,188
Cash flows from investing activities:			
Purchase of property and equipment	(349,862)	(233,364)	(5,838)
Proceeds from sale or disposal of property and equipment	—	2,500	11,562
Purchase of intangible assets	—	—	(10,000)
Net cash used in investing activities	(349,862)	(230,864)	(4,276)
Cash flows from financing activities:			
Proceeds from warrants exercised	506,000	—	—
Proceeds from issuance of preferred stock allocated to derivative liabilities	—	—	6,000,000
Payment of stock issuance costs	—	—	(579,036)
Payment of debt discount and debt issuance costs	—	—	(221,964)
Payments on notes payable	(225,560)	(172,595)	(229,586)
Payments on finance lease liabilities	(7,962)	(17,443)	(28,857)
Issuance of common stock for PIPE transaction	—	1,000,000	—
Payment of stock issuance costs	—	(120,000)	—
Net cash provided by financing activities	272,478	689,962	4,940,557
(Decrease) increase in cash	(337,212)	609,307	5,935,469
Cash at beginning of period	7,352,183	6,742,876	1,412,108
Cash at end of period	\$ 7,014,971	\$ 7,352,183	\$ 7,347,577
Supplemental disclosures of cash flow information:			
Cash paid for interest	\$ 38,266	\$ 36,734	\$ 85,147
Cash paid for income taxes	\$ —	\$ —	\$ 866
Supplemental schedule of non-cash investing and financing activities:			
Debt conversion of long-term notes payable and accrued interest, net of unamortized debt discount and debt issuance costs	\$ —	\$ 1,194,855	\$ —
Issuance of common stock and common stock purchase warrants for debt conversion	\$ —	\$ 6,400,463	\$ —
Debt extension fees and other financing costs added to note principal	\$ —	\$ —	\$ 484,377
Issuance of common stock for services rendered	\$ —	\$ —	\$ 658,682
Insurance premiums financed through issuance of note payable	\$ —	\$ —	\$ 128,437
Equipment purchase financed through issuance of note payable	\$ —	\$ —	\$ 115,111

See accompanying notes to the unaudited condensed consolidated financial statements.

PROGRESSIVE CARE INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)

Unless the context requires otherwise, references to the “Company,” “we,” “us,” “our,” “our Company,” or “our business” refer to Progressive Care Inc. and its subsidiaries.

Note 1. Organization & Nature of Operations

Progressive Care Inc. (“Progressive”) was incorporated under the laws of the state of Delaware on October 31, 2006.

Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901”), Touchpoint RX, LLC doing business as Pharmco Rx 1002, LLC (“Pharmco 1002”), Family Physicians RX, Inc. doing business as PharmcoRx 1103 and PharmcoRx 1204 (“FPRX” or “Pharmco 1103” and “Pharmco 1204”) (pharmacy subsidiaries collectively referred to as “Pharmco”), and ClearMetrX Inc. (“ClearMetrX”) is a personalized healthcare services company that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers.

Pharmco 901 was formed on November 29, 2005 as a Florida Limited Liability Company and is a 100% owned subsidiary of Progressive. Pharmco 901 was acquired by Progressive on October 21, 2010. We currently deliver prescriptions to Florida’s diverse population and ship medications to patients in states where we hold non-resident pharmacy licenses as well. We currently hold Florida Community Pharmacy Permits at all Florida pharmacy locations and our Pharmco 901 location is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Illinois, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah. We are able to dispense to patients in the state of Massachusetts without a non-resident pharmacy license because Massachusetts does not require such a license for these activities.

Pharmco 1103 is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides Pharmco’s pharmacy services to Miami-Dade County, Broward County, the Orlando/Tampa corridor, and the Treasure Coast of Florida. Progressive acquired all the ownership interests in Pharmco 1103 in a purchase agreement entered into on June 1, 2019.

Pharmco 1002 is a pharmacy located in Palm Springs, Florida that provides Pharmco’s pharmacy services to Palm Beach, St. Lucie and Martin Counties, Florida. Progressive acquired all the ownership interests in Pharmco 1002 in a purchase agreement entered into on July 1, 2018.

ClearMetrX was formed on June 10, 2020 and provides third-party administration (“TPA”) services to 340B covered entities. ClearMetrX also provides data analytics and reporting services to support and improve care management for health care organizations.

RXMD Therapeutics was formed on October 1, 2019. RXMD Therapeutics has had no operating activity to date.

Note 2. Basis of Presentation and Principles of Consolidation

The accompanying Unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) on a basis consistent with reporting interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements.

On June 30, 2023, NextPlat Corp (“NextPlat”), Charles M. Fernandez, Chairman and Chief Executive Officer of the Company, and Rodney Barreto, Vice-Chairman of the Company, entered into a voting agreement whereby at any annual or special shareholders meeting of the Company’s stockholders Messrs. Fernandez and Barreto agreed to vote all of the common stock shares that they own in the same manner that NextPlat votes its Common Stock and equivalents. On July 1, 2023, NextPlat, Messrs. Fernandez and Barreto exercised common stock purchase warrants and were issued common stock shares by the Company. After the exercise of the common stock purchase warrants, NextPlat, Messrs. Fernandez and Barreto collectively owned 53% of the Company’s voting common stock. Collectively, the exercise of the common stock purchase warrants and the entry into the voting agreement constituted a change in control in Progressive Care. As a result of the change in control, the Company elected to apply push-down accounting in accordance with Accounting Standards Codification (“ASC”) 805, *Business Combinations*. The application of push-down accounting created a new basis of accounting for all assets and liabilities based on their fair value at the date of acquisition, with few exceptions permissible under US GAAP. As a result, the Company’s financial position, results of operations, and cash flows subsequent to the acquisition on July 1, 2023 have been segregated to indicate pre-acquisition and post-acquisition periods. The pre-acquisition period through June 30, 2023 is referred to as the “Predecessor Company”. The post-acquisition period, July 1, 2023 and forward, includes the impact of push-down accounting and is referred to as the “Successor Company”.

Interim results are not necessarily indicative of the results that may be expected for the full year. Accordingly, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statements and notes thereto included in the 2022 Form 10-K. In the opinion of management, the Unaudited Condensed Consolidated Financial Statements contain all adjustments (consisting principally of normal recurring accruals) necessary for a fair presentation of the condensed consolidated balance sheets, statements of operations, statements of stockholders’ equity and statements of cash flows for such interim periods presented.

The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Certain 2022 financial information has been reclassified to conform to the 2023 presentation. Such reclassifications do not impact the Company’s previously reported financial position or net income (loss). On the Condensed Consolidated Statements of Operations, Interest income for the three and nine months ended September 30, 2022, has been reported on a separate line item apart from Selling, general, and administrative in the current period financial statements. Additionally, Revenues, net, Costs of revenue, and Operating expenses have been disaggregated for all periods presented on the Condensed Consolidated Statements of Operations.

Note 3. Summary of Significant Accounting Policies

The significant accounting policies of the Company were described in Note 3 to the Audited Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2022. Except as described above in Note 2, there have been no material changes to the Company’s significant accounting policies for the nine months ended September 30, 2023.

Cash

The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may exceed federally insured limits of \$250,000. The Company had approximately \$1.6 million that was uninsured as of September 30, 2023. In July 2023, the Company entered into a deposit placement agreement for Insured Cash Sweep Services (“ICS”). This service is a secure and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of \$250,000.

Concentrations

Suppliers:

The Company had significant concentrations with one vendor. The purchases from this significant vendor were 99% of total vendor purchases for the three months ended September 30, 2023. The purchases from this significant vendor were 97%, 93% and 95% of total vendor purchases for the six months ended June 30, 2023 and the three and nine months ended September 30, 2022, respectively.

Customers:

In addition, reimbursements from three significant pharmacy benefit managers (“PBMs”) were as follows:

	Successor	Predecessor	
	Three Months Ended September 30, 2023	Six Months Ended June 30, 2023	Nine Months Ended September 30, 2022
A	35%	28%	11%
B	31%	38%	52%
C	16%	19%	23%

Recently Adopted Accounting Standards

In August 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-04, “Liabilities (Topic 405) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 121”, to amend and add various SEC paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Bulletin No. 121. The Company adopted this conforming guidance upon issuance and the adoption had no material impact on our condensed consolidated financial statements and related disclosures.

In July 2023, the FASB issued ASU 2023-03, “Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718)”, to amend various SEC paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The Company adopted this conforming guidance upon issuance and the adoption had no material impact on our condensed consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which introduces an impairment model based on expected, rather than incurred, losses. Additionally, it requires expanded disclosures regarding (a) credit risk inherent in a portfolio and how management monitors the portfolio’s credit quality; (b) management’s estimate of expected credit losses; and (c) changes in estimates of expected credit losses that have taken place during the period. In November 2018, the FASB issued ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses.” This ASU clarifies receivables from operating leases are accounted for using the lease guidance and not as financial instruments. In April 2019, the FASB issued ASU 2019-04, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments.” This ASU clarifies various scoping and other issues arising from ASU 2016-13. In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments.” This ASU improves the Codification and amends the interaction of Topic 842 and Topic 326. ASU 2016-13 and related amendments are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance effective January 1, 2023 and the adoption had no material impact on our condensed consolidated financial statements and related disclosures. On an ongoing basis, the Company will contemplate forward-looking economic conditions in recording lifetime expected credit losses for the Company’s financial assets measured at cost.

Note 4. Business Combination

As referenced in Note 2, the Company has applied push-down accounting to its financial statements, which resulted in the initial recognition of its assets and liabilities as of the acquisition date, July 1, 2023. The assets and liabilities were measured at estimated fair values primarily using Level 3 inputs. Estimates of fair value represent management’s best estimate which require a complex series of judgments about future events and uncertainties. Third-party valuation specialists were engaged to assist in the valuation of these assets and liabilities. The fair values of the Company’s current assets and current liabilities were assumed to approximate their carrying values. The estimated fair values of the Company’s identifiable intangible assets consist of trade name, developed technology, and pharmacy records. The fair values of trade name and developed technology were estimated by applying an income approach, specifically a relief from royalty method. The fair value of pharmacy records was estimated by applying a market approach. The estimated fair value of the Company’s building and land, included in property and equipment, net, was estimated by applying a sales comparison approach while vehicles, furniture and equipment, leasehold improvements and fixtures, and computer equipment were assumed to approximate their carrying value. These fair value measurements are based on significant inputs not observable in the market, and thus represent Level 3 measurements. Goodwill was recorded as the excess of the estimated enterprise value over the sum of the fair value amounts allocated to the Company’s assets and liabilities. The goodwill is not deductible for tax purposes.

The following table summarizes the preliminary allocation of the fair value of the consideration to the assets and liabilities of the Company on July 1, 2023. The preliminary allocation to certain assets and/or liabilities may be adjusted by material amounts as the Company continues to finalize its fair value estimates. The total consideration is based on the fair value of the Company’s common stock outstanding at July 1, 2023, which was 6,162,343 common shares outstanding and a fair market value of \$4.45 per share.

Total consideration	\$ 27,422,000
Fair value of identifiable net assets:	
Cash	7,352,000
Accounts receivable, net	6,478,000
Receivables - other, net	506,000
Inventory	1,631,000
Prepaid expenses	220,000
Property and equipment, net	2,883,000
Right-of-use assets, net	405,000
Intangible assets, net:	
Trade name ¹	4,060,000
Developed technology ²	2,560,000
Pharmacy records ²	8,100,000
Deposits	39,000
Accounts payable and accrued expenses	(8,196,000)
Notes payable and accrued interest - current portion	(149,000)
Lease liabilities - current portion	(208,000)
Notes payable - long-term	(1,173,000)
Lease liabilities - long-term	(230,000)
Total fair value of net assets	<u>\$ 24,278,000</u>
Goodwill	<u>\$ 3,144,000</u>

(1) 10 year amortization period

(2) 5 year amortization period

Note 5. Fair Value Measurements

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

- *Cash, accounts receivable, and accounts payable and accrued liabilities:* The amounts reported in the accompanying Condensed Consolidated Balance Sheets approximate fair value due to their short-term nature.
- *Notes payable and lease liabilities:* The carrying amount of notes payable approximated fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing. The carrying value of lease liabilities approximated fair value due to the implicit rate in the lease in relation to the Company's borrowing rate and the duration of the leases (Level 2 inputs).

Common Stock Purchase Warrants

As of September 30, 2023, the Company had common stock purchase warrants classified as Level 3 equity instruments. The fair value of the common stock purchase warrants on the date of issuance was approximately \$4.6 million. As of September 30, 2023, the fair value of the remaining common stock purchase warrants was approximately \$1.0 million. The Company used the Monte Carlo simulation model for valuation of the common stock purchase warrants. Key inputs into the Monte Carlo simulation model were as follows at the valuation date: risk-free interest rate: 3.5%-3.7%; expected term: 3-5.6 years; expected volatility: 93%-102%; exercise price: \$2.20. For additional information on the initial issuance and subsequent exercise of the common stock purchase warrants, see also "Note 14. Stockholder's Equity, Common Stock and Common Stock Purchase Warrants."

Note 6. Revenue

The Company recognizes prescription revenue and 340B contract revenue from dispensing prescription drugs at the time the drugs are physically delivered to a customer or when a customer picks up their prescription or purchases merchandise at the store, which is the point in time when control transfers to the customer. Each prescription claim is considered an arrangement with the customer and is a separate performance obligation. Payments are received directly from the customer at the point of sale, or the customers' insurance provider is billed electronically. For third-party medical insurance and other claims, authorization is obtained to ensure payment from the customer's insurance provider before the medication is dispensed to the customer. Authorization is obtained for these sales electronically and a corresponding authorization number is issued by the customers' insurance provider.

The Company accrues an estimate of PBM fees, including direct and indirect remuneration ("DIR") fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known.

The Company recognizes COVID-19 testing revenue when the tests are performed and results are delivered to the customer. Each test is considered an arrangement with the customer and is a separate performance obligation. Payment is generally received in advance from the customer.

Billings for most prescription orders are with third-party payers, including Medicare, Medicaid, and insurance carriers. Customer returns are nominal. Prescription revenue, net of PBM fees, for the Successor Company was 80% of total revenue for the three months ended September 30, 2023. Prescription revenue, net of PBM fees, for the Predecessor Company was 84%, 86%, and 86% of total revenue for the six months ended June 30, 2023 and the three and nine months ended September 30, 2022, respectively.

The following table disaggregates net revenues by categories:

	<u>Successor</u>	<u>Predecessor</u>
	<u>Three Months Ended September 30, 2023</u>	<u>Three Months Ended September 30, 2022</u>
Sales of products, net		
Prescription revenue, net of PBM fees	\$ 9,872,908	\$ 8,753,591
COVID-19 testing revenue	5,943	235,221
Other revenue	9,039	903
Subtotal	<u>9,887,890</u>	<u>8,989,715</u>
Revenues from services:		
340B contract revenue	<u>2,471,560</u>	<u>1,154,166</u>
Revenues, net	<u>\$ 12,359,450</u>	<u>\$ 10,143,881</u>

	<u>Successor</u>	<u>Predecessor</u>	
	<u>Three Months Ended September 30, 2023</u>	<u>Six Months Ended June 30, 2023</u>	<u>Nine Months Ended September 30, 2022</u>
Sales of products, net			
Prescription revenue, net of PBM fees	\$ 9,872,908	\$ 19,218,508	\$ 26,023,243
COVID-19 testing revenue	5,943	53,603	1,894,434
Other revenue	9,039	5,703	2,560
Subtotal	<u>9,887,890</u>	<u>19,277,814</u>	<u>27,920,237</u>
Revenues from services:			
340B contract revenue	<u>2,471,560</u>	<u>3,670,215</u>	<u>2,248,223</u>
Revenues, net	<u>\$ 12,359,450</u>	<u>\$ 22,948,029</u>	<u>\$ 30,168,460</u>

Note 7. Earnings (Loss) per Share

Basic weighted average (loss) earnings per share (“EPS”) is computed by dividing net (loss) income available to common shareholders by the weighted average number of common shares outstanding during the year, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the year including common stock purchase warrants and stock options, using the treasury stock method, and convertible debt, using the if converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive.

The components of basic and diluted EPS were as follows. For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted weighted average loss per common share and basic weighted average loss per common share being equivalent.

	<u>Successor</u> Three Months Ended September 30, 2023	<u>Predecessor</u> Three Months Ended September 30, 2022
Net loss attributable to common shareholders	\$ (1,374,748)	\$ (9,503,906)
Basic weighted average common shares outstanding	6,173,444	2,886,408
Potentially dilutive common shares	—	—
Diluted weighted average common shares outstanding	6,173,444	2,886,408
Basic weighted average loss per common share	\$ (0.22)	\$ (3.29)
Diluted weighted average loss per common share	\$ (0.22)	\$ (3.29)
Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share:		
Common stock purchase warrants	487,018	590,909
Stock options	10,566	99,170
	497,584	690,079

	<u>Successor</u> Three Months Ended September 30, 2023	<u>Predecessor</u> Six Months Ended June 30, 2023	<u>Predecessor</u> Nine Months Ended September 30, 2022
Net loss attributable to common shareholders	\$ (1,374,748)	\$ (4,767,365)	\$ (11,746,103)
Basic weighted average common shares outstanding	6,173,444	3,895,532	2,786,849
Potentially dilutive common shares	—	—	—
Diluted weighted average common shares outstanding	6,173,444	3,895,532	2,786,849
Basic weighted average loss per common share	\$ (0.22)	\$ (1.22)	\$ (4.21)
Diluted weighted average loss per common share	\$ (0.22)	\$ (1.22)	\$ (4.21)
Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share:			
Common stock purchase warrants	487,018	171,695	590,909
Stock options	10,566	—	99,170
	497,584	171,695	690,079

Note 8. Accounts Receivable – Trade, net

Accounts receivable consisted of the following at:

	<u>Successor</u> September 30, 2023	<u>Predecessor</u> December 31, 2022
Gross accounts receivable – trade	\$ 7,484,809	\$ 3,875,686
Less: allowance for doubtful accounts	(237,000)	(203,900)
Accounts receivable – trade, net	\$ 7,247,809	\$ 3,671,786

The Successor Company recognized bad debt expense in the amount of approximately \$12,000 for the three months ended September 30, 2023. The Predecessor Company recognized bad debt expense (recovery) in the amount of approximately \$21,100, (\$2,300), and (\$20,000) for the six months ended June 30, 2023, three months ended September 30, 2022, and nine months ended September 30, 2022, respectively.

Accounts receivable – trade, net for the Predecessor Company as of January 1, 2022 and September 30, 2022 were approximately \$2.2 million and \$2.8 million, respectively.

Note 9. Receivables – Other, net

Receivables – Other, net consisted of the following:

	<u>Successor</u> <u>September</u> <u>30, 2023</u>	<u>Predecessor</u> <u>December 31,</u> <u>2022</u>
Covered entities	\$ 2,036,629	\$ —
Performance bonuses	861,040	1,224,428
Vendor credits	—	503,056
Other	47,658	277,321
	<u>\$ 2,945,327</u>	<u>\$ 2,004,805</u>

Receivables from covered entities represent the cost of inventory replenishments related to 340B contracts. Vendor credit receivables are timing differences of physical inventory returned to the vendor and the Company receiving the credit. Performance bonuses, paid annually by PBMs, are estimated based on historical pharmacy performance and prior payments received. Other receivables are loans to employees.

Note 10. Property and Equipment, net

Property and equipment, net consisted of the following:

	<u>Successor</u> <u>September</u> <u>30, 2023</u>	<u>Predecessor</u> <u>December 31,</u> <u>2022</u>
Building	\$ 2,116,000	\$ 1,651,069
Vehicles	491,466	251,715
Furniture and equipment	364,135	423,829
Land	184,000	184,000
Leasehold improvements and fixtures	75,825	276,614
Computer equipment	808	101,230
Building improvements	—	513,075
Total	3,232,234	3,401,532
Less: accumulated depreciation	(64,714)	(818,779)
Property and equipment, net	<u>\$ 3,167,520</u>	<u>\$ 2,582,753</u>

As of July 1, 2023, building, building improvements, and land were revalued at fair value as a result of the application of push-down accounting. See “Note 4. Business Combination” for a summary of amounts recognized for each major class of asset and liabilities, after application of push-down accounting.

Depreciation expense for the Successor Company was approximately \$65,000 for the three months ended September 30, 2023. Depreciation expense for the Predecessor Company was approximately \$52,000, \$33,000, and \$97,000 for the six months ended June 30, 2023 and the three and nine months ended September 30, 2022, respectively.

Note 11. Goodwill and Intangible Assets

Goodwill

As of September 30, 2023, goodwill increased to \$3.1 million from \$1.4 million as of December 31, 2022. The increase in goodwill was a result of the excess amount of the estimated enterprise value over the sum of the fair value amounts allocated to the Company’s assets and liabilities as a result of the change in control on July 1, 2023.

Intangible Assets

Intangible assets consisted of the following at:

	<u>Successor</u> <u>September</u> <u>30, 2023</u>	<u>Predecessor</u> <u>December 31,</u> <u>2022</u>
Pharmacy records	\$ 8,100,000	\$ 263,000
Tradenames	4,060,000	362,000
Developed technology	2,560,000	—
Software	—	86,424
Non-compete agreements	—	166,000
Website	—	67,933
Subtotal	14,720,000	945,357
Less: accumulated amortization	(634,503)	(818,661)
Net intangible assets	<u>\$ 14,085,497</u>	<u>\$ 126,696</u>

As of July 1, 2023, intangible assets were revalued at fair value as a result of the application of push-down accounting. See “Note 4. Business Combination” for a summary of amounts recognized for each major class of asset and liabilities, after application of push-down accounting.

Amortization of intangible assets for the Successor Company was approximately \$635,000 for the three months ended September 30, 2023. Amortization of intangible assets for the Predecessor Company was approximately \$24,400, \$8,000, and \$23,900 for the six months ended June 30, 2023 and the three and nine months ended September 30, 2022, respectively. The following table represents the total estimated future amortization of intangible assets:

<u>Year</u>	<u>Successor</u> <u>Amount</u>
2023 (remaining three months)	\$ 634,497

2024	2,538,000
2025	2,538,000
2026	2,538,000
2027	2,538,000
Thereafter	3,299,000
Total	<u>\$ 14,085,497</u>

Note 12. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following at:

	<u>Successor</u> <u>September</u> <u>30, 2023</u>	<u>Predecessor</u> <u>December 31,</u> <u>2022</u>
Accounts payable – trade	\$ 11,212,272	\$ 6,517,496
Accrued payroll and payroll taxes	314,017	228,957
Accrued PBM fees	650,000	500,589
Other accrued liabilities	200,565	137,294
Total	\$ 12,376,854	\$ 7,384,336

Note 13. Notes Payable

Notes payable consisted of the following at:

	<u>Successor</u> <u>September</u> <u>30, 2023</u>	<u>Predecessor</u> <u>December 31,</u> <u>2022</u>
A. Convertible note payable and accrued interest - collateralized	\$ —	\$ 2,837,910
B. Mortgage note payable - commercial bank - collateralized	1,162,004	1,225,913
C. Note payable - uncollateralized	25,000	25,000
D. Notes payable - collateralized	98,029	137,017
Insurance premiums financing	—	70,302
Subtotal	1,285,033	4,296,142
Less: unamortized debt discount	—	(1,820,585)
Total	1,285,033	2,475,557
Less: current portion of notes payable	(145,736)	(226,931)
Long-term portion of notes payable	<u>\$ 1,139,297</u>	<u>\$ 2,248,626</u>

The corresponding notes payable above are more fully discussed below:

(A) Convertible Note Payable – collateralized

NextPlat Investors

In August 2022, the Predecessor Company entered into the Modification Agreement with the NextPlat investors wherein the terms were modified for an existing Secured Convertible Promissory Note originally held by Iliad Research (the “Note”) and sold to the NextPlat investors (the “NextPlat Investors Note”). The NextPlat investors purchased the Note as part of a Confidential Note Purchase and Release Agreement between Iliad Research and the NextPlat investors. As of the date of the Securities Purchase Agreement (“SPA”), the aggregate amount of principal and interest outstanding on the NextPlat Investors Note was approximately \$2.8 million. As part of the Modification Agreement, the NextPlat investors agreed to modify the following terms of the NextPlat Investors Note:

1. The Maturity Date was extended to August 31, 2027.
2. The Outstanding Balance bore interest at the simple annual rate of five percent (5%) per annum.
3. The Predecessor Company was prohibited from prepaying the Note.
4. The Conversion Price for the Note was modified to a fixed price of \$4.00 per share of common stock.
5. The Note provided for mandatory conversion upon the later to occur of (a) the completion of the Predecessor Company’s reverse stock split, or (b) the listing of the Company’s common stock on a national exchange, including the Nasdaq Capital Market, the Nasdaq Global Market, or the New York Stock Exchange.

On May 5, 2023, the Predecessor Company entered into a Debt Conversion Agreement (the “DCA”) with NextPlat and the other holders (the “Holders”) of the Amended and Restated Secured Convertible Promissory Note. Pursuant to the DCA, NextPlat and the other Holders agreed to modify and convert the total \$2.9 million of outstanding principal and accrued and unpaid interest to Common Stock at a conversion price of \$2.20 per share (the “Debt Conversion”) for a total of 1,312,379 shares. Additionally, the Predecessor Company issued 330,000 common stock purchase warrants to certain existing Progressive Care investors to induce them to approve the Debt Conversion (the “Inducement Warrants”). The Inducement Warrants were recorded at fair value as equity instruments. The Debt Conversion was recorded using inducement accounting and resulted in a total debt conversion expense of approximately \$5.2 million for the six months ended June 30, 2023. Debt conversion expense consisted of debt issuance costs and debt discount of approximately \$1.7 million, the fair value of the common stock purchase warrants issued of approximately \$4.6 million, partially offset by the loss from inducement accounting of approximately \$1.1 million.

Debt Issuance Costs and Debt Discount Associated with the NextPlat Investors Note - Predecessor Company

Debt issuance costs consisted of fees incurred from the Placement Agent and Investment Advisor associated with the NextPlat Investors Debt Modification Agreement. Debt discount consisted of the discount recorded from the issuance of approximately 105,000 shares of common stock to the NextPlat Investors as consideration for the Debt Modification Agreement.

Debt issuance costs and debt discount were amortized to interest expense over the term of the related debt using the straight-line method. There was no amortization expense for debt issuance costs and debt discount for the three months ended September 30, 2023. Total amortization expense for the six months ended June 30, 2023 was approximately \$128,000.

As a result of the Debt Conversion, the remaining balance of debt issuance costs and debt discount of approximately \$1.7 million at the date of the Debt Conversion was written off and recognized as part of debt conversion expense for the six months ended June 30, 2023 on the Condensed Consolidated Statements of Operations.

(B) Mortgage Note Payable – collateralized

In 2018, Pharmco 901 closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of \$1,530,000. The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on December 14, 2028 and is subject to a prepayment penalty. Principal and interest will be repaid through 119 regular payments of \$11,901 that began in January 2019, with the final payment of all principal and accrued interest not yet paid on December 14, 2028. Note repayment is guaranteed by Progressive Care Inc.

(C) Note Payable – Uncollateralized

As of September 30, 2023 and December 31, 2022, the uncollateralized note payable represents a noninterest-bearing loan that is due on demand from an investor.

(D) Notes Payable – Collateralized

In September 2019, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to pay off a capital lease obligation on pharmacy equipment in the amount of approximately \$85,000. The terms of the promissory note payable require 48 monthly payments of \$2,015, including interest at 6.5%. The balance outstanding on the note payable was due and paid in full during the third quarter of 2023 and no balance remains as of September 30, 2023. The balance outstanding on the note payable as of December 31, 2022 was approximately \$16,000.

In April 2021, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately \$30,000. During September 2021, pharmacy equipment was returned since the installation was cancelled and the note was amended. The amended promissory note payable requires 46 monthly payments of \$331, including interest at 6.9%. The balance outstanding as of September 30, 2023 and December 31, 2022 on the note payable was approximately \$6,500 and \$9,000, respectively.

In July 2022, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately \$90,000. The terms of the promissory note payable require 60 monthly payments of \$1,859, including interest at 8.78% starting January 2023. The balance outstanding on the note payable was approximately \$78,000 and \$90,000 as of September 30, 2023 and December 31, 2022, respectively.

In September 2022, the Predecessor Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase a vehicle in the amount of approximately \$25,000. The terms of the promissory note payable require 24 monthly payments of \$1,143, including interest at 8.29% starting October 2022. The balance outstanding on the note payable was approximately \$13,000 and \$22,000 as of September 30, 2023 and December 31, 2022, respectively.

Principal outstanding as of September 30, 2023, is expected to be repayable as follows:

<u>Year</u>	<u>Successor</u> <u>Amount</u>
2023 (remaining three months)	\$ 53,829
2024	121,126
2025	114,419
2026	118,630
2027	123,597
Thereafter	753,432
Total	\$ 1,285,033

Interest expense on these notes payable for the Successor Company was approximately \$15,000 for the three months ended September 30, 2023. Interest expense on notes payable, exclusive of debt discount and debt issue cost amortization, for the Predecessor Company was approximately \$82,000, \$75,000, and \$325,000 for the six months ended June 30, 2023 and the three and nine months ended September 30, 2022, respectively.

Note 14. Stockholders' Equity

Preferred Stock

The Company has 10,000,000 shares of preferred stock authorized. As of September 30, 2023 and December 31, 2022, 100,000 shares are designated as Series B Preferred Stock, par value \$0.001 per share, and 9,900,000 shares are undesignated preferred shares, par value \$0.001 per share.

On August 30, 2022, pursuant to a SPA with NextPlat, the Predecessor Company sold 3,000 units wherein each unit is made up of one share of Series B Convertible Preferred Stock, \$0.001 par value, and Investor Warrants. Each warrant entitles the holder to purchase one share of Series B Convertible Preferred Stock at an exercise price of \$2,000. The Investor Warrants may also be exercised, in whole or in part, by means of a cashless exercise. The Series B Convertible Preferred Stock has a stated value of \$2,000 per share and each Preferred Stock share has the equivalent voting rights of 500 common stock shares. Each share of Series B Convertible Preferred Stock is convertible at any time at the option of the holder into shares of the Company's common stock determined by dividing the stated value by the conversion price of \$4.00.

The Series B Convertible Preferred Stock ranks senior to our common stock as to distribution of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The shares of Series B Convertible Preferred Stock shall have a liquidation preference to all other class of stock of the Company in the amount of \$2,000 per share. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series B Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company (i) \$2,000 per share plus (ii) the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock which amounts shall be paid *pari passu* with all holders of common stock.

With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.

Common Stock and Common Stock Purchase Warrants

On December 29, 2022, the Predecessor Company effected a 1-for-200 reverse stock split of common stock and the number of shares of common stock authorized to issue was reduced to 100 million. All fiscal year 2022 common stock share information has been retrospectively adjusted to reflect the reverse stock split.

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB Accounting Standards Codification ("ASC") 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter.

On May 5, 2023, the Predecessor Company entered into an SPA with NextPlat, pursuant to which NextPlat agreed to purchase 455,000 newly issued units of securities from the Predecessor Company (the "Units") at a price per Unit of \$2.20 for an aggregate purchase price of \$1.0 million (the "Unit Purchase"). Each Unit consists of one share of common stock, par value \$0.0001 per share, of Progressive Care ("Common Stock") and one common stock purchase warrant to purchase a share of Common Stock (the "PIPE Warrants"). The PIPE Warrants have a three-year term and will be immediately exercisable. Each PIPE Warrant is exercisable at \$2.20 per share of Common Stock. The Predecessor Company received cash proceeds of \$880,000, net of placement agent commission of \$70,000 and legal fees of \$50,000. The Company accounted for the PIPE Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the PIPE Warrants was approximately \$1.0 million. On July 1, 2023, NextPlat exercised the PIPE Warrants on a cashless basis and was issued 230,056 common stock shares.

Also on May 5, 2023, the Predecessor Company entered into a DCA with NextPlat and the other Holders of that certain Amended and Restated Secured Convertible Promissory Note, dated as of September 2, 2022, made by the Predecessor Company in the original face amount of \$2.8 million (the "Note"). Pursuant to the DCA, NextPlat and the other Holders agreed to modify and convert the total \$2.9 million of outstanding principal and accrued and unpaid interest to common stock at a conversion price of \$2.20 per share (the "Debt Conversion"). Of the total 1,312,379 shares of common stock issued upon conversion of the Note pursuant to the DCA, NextPlat received 570,599 shares, Charles M. Fernandez, the Company's Chairman and Chief Executive Officer, received 228,240 shares, and Rodney Barreto, the Company's Vice-Chairman of the Board of Directors, received 228,240 shares. In addition, each of the Holders also received a common stock purchase warrant to purchase one share of common stock for each share of common stock they received upon conversion of the Note (the "Conversion Warrants"). The Conversion Warrants have a three-year term and will be immediately exercisable. Each Conversion Warrant is exercisable at \$2.20 per share of Common Stock. The Company accounted for the Conversion Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Conversion Warrants was approximately \$2.7 million. On July 1, 2023, NextPlat and Messrs. Fernandez and Barreto exercised the Conversion Warrants. NextPlat exercised 230,000 Conversion Warrants on a cash basis and paid consideration in the amount of \$506,000 and was issued 230,000 common stock shares. NextPlat exercised the remaining 340,599 Conversion Warrants on a cashless basis and was issued 172,213 common stock shares. Messrs. Fernandez and Barreto exercised the Conversion Warrants on a cashless basis and were each issued 115,402 common stock shares. As of September 30, 2023, the fair value of the remaining Conversion Warrants was approximately \$0.6 million.

At the same time as the SPA and DCA, the Predecessor Company and NextPlat entered into a First Amendment (the "Amendment") to that certain Securities Purchase Agreement dated November 16, 2022 (the "Debenture Purchase Agreement"). Under the Debenture Purchase Agreement, the Predecessor Company agreed to issue, and NextPlat agreed to purchase, from time to time during the three-year term of the Debenture Purchase Agreement, up to an aggregate of \$10.0 million of secured convertible debentures to NextPlat (the "Debentures"). Pursuant to the Amendment, NextPlat and the Predecessor Company agreed to amend the Debenture Purchase Agreement and the form of Debenture to have a conversion price of \$2.20 per share. As of September 30, 2023, no Debentures have been purchased by NextPlat under the Debenture Purchase Agreement.

Dawson James Securities, Inc. (the "Placement Agent") served as placement agent for the Unit Purchase. In consideration for the Placement Agent's services, the Predecessor Company issued to the Placement Agent and its affiliates warrants to purchase 91,000 shares of Common Stock (the "Placement Agent Warrants"). The Placement Agent Warrants have a five-year term and will be exercisable in December 2023. Each Placement Agent Warrant is exercisable at \$2.20 per share of Common Stock. The Company accounted for the Placement Agent Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Placement Agent Warrants was approximately \$0.2 million.

In addition, the Predecessor Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the "Inducement Warrants"). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three-year term and will be immediately exercisable. Each Inducement Warrant is exercisable at \$2.20 per share of Common Stock. The Company accounted for the Inducement Warrants in accordance with the guidance contained in ASC 480 and were classified as equity instruments. On the date of issuance, the fair value of the Inducement Warrants was approximately \$0.7 million. On July 1, 2023, Messrs. Fernandez and Barreto exercised the Inducement Warrants on a cashless basis and were issued 96,068 and 15,169 common stock shares, respectively. As of September 30, 2023, the fair value of the remaining Inducement Warrants was approximately \$0.2 million.

Note 15. Stock-Based Compensation

Stock-based compensation is recorded in selling, general, and administrative expenses in the Condensed Consolidated Statement of Operations. The Successor Company recorded total stock-based compensation expense of approximately \$1.2 million for the three months ended September 30, 2023 relating to shares of common stock issued and accelerated vesting of stock options to directors for services provided. The Predecessor Company recorded total stock-based compensation expense of approximately \$0.3 million, \$1.4 million, and \$1.4 million for the six months ended June 30, 2023 and the three and nine months ended September 30, 2022, respectively, relating to shares of common stock issued to directors for services provided. There were no income tax benefits recognized from stock-based compensation during the respective periods due to cumulative losses and valuation allowances.

Note 16. Commitments and Contingencies

Legal Matters

On May 3, 2022, a complaint was filed by the Plaintiff Positive Health Alliance, Inc. (“PHA”) against Pharmco LLC in the U.S. Circuit Court of Miami Dade, Florida, alleging that defendant failed to pay amounts due and owing to PHA under the parties’ contract for discounted prescription drugs. PHA is seeking judgment against Pharmco for compensatory damages in the amount of \$407,504, plus attorneys’ fees and costs. PHA and Pharmco entered into a settlement agreement on July 1, 2022, pursuant to which Pharmco paid to PHA the total amount of \$407,504 in 13 installment payments. The complaint was dismissed with prejudice on July 8, 2022. The last installment payment was paid during the third quarter of 2023 and no balance remained outstanding as of September 30, 2023. The balance outstanding was approximately \$280,000 as of December 31, 2022 (recorded in Accounts payable and accrued liabilities).

On June 8, 2022, the Company filed a complaint against KeyCentrix, LLC (“KCL”), in the U.S. District Court for the Southern District of Florida, alleging fraudulent inducement, breach of express warranty and breach of implied warranty. The complaint stems from an agreement by KCL to license to the Predecessor Company certain pharmacy management software known as “Newleaf” for use in the operations of pharmacies operated by the Company.

Note 17. Related Party Transactions

Successor Company

During the three months ended September 30, 2023, the Successor Company paid \$60,000 to NextPlat as management fees in accordance with the amended Management Services Agreement (the “Management Agreement”) dated May 1, 2023.

On July 1, 2023, NextPlat, Charles M. Fernandez, and Rodney Barreto exercised common stock purchase warrants and were issued common stock shares by the Company. NextPlat exercised common stock purchase warrants on a cashless basis and was issued 402,269 common stock shares. NextPlat also exercised common stock purchase warrants on a cash basis and paid consideration in the amount of \$506,000 and was issued 230,000 common stock shares. Mr. Fernandez exercised common stock purchase warrants on a cashless basis and was issued 211,470 common stock shares. Mr. Barreto exercised common stock purchase warrants on a cashless basis and was issued 130,571 common stock shares.

Predecessor Company

On August 30, 2022, NextPlat, Charles M. Fernandez, Rodney Barreto, and certain other purchasers purchased from Iliad Research a Secured Convertible Promissory Note, dated March 6, 2019, made by the Predecessor Company to Iliad (the “Note”). The accrued and unpaid principal and interest under the note at the time of the purchase was approximately \$2.8 million. In connection with the Note Purchase, NextPlat, Messrs. Fernandez and Barreto and the other purchasers of the Note entered into a Debt Modification Agreement with the Predecessor Company. In consideration of the concessions in the Debt Modification Agreement, the Predecessor Company issued 105,000 shares of its common stock to the purchasers of the Note, of which NextPlat, Messrs. Fernandez and Barreto, received 45,653, 18,261, and 18,261 shares, respectively.

On February 1, 2023, the Predecessor Company entered into the Management Agreement with NextPlat Corp to provide certain management and administrative services to the Predecessor Company for \$25,000 per month fee. On May 1, 2023, the Management Agreement was amended to update the fee to \$20,000 per month. During the six months ended June 30, 2023, the Predecessor Company paid \$115,000 to NextPlat as management fees.

On May 5, 2023, the Predecessor Company entered into an SPA with NextPlat, pursuant to which NextPlat agreed to purchase 455,000 newly issued Units of securities from the Predecessor Company at a price per Unit of \$2.20 for an aggregate purchase price of \$1.0 million (the “Unit Purchase”). Each Unit consists of one share of common stock, par value \$0.0001 per share, and one common stock purchase warrant to purchase a share of common stock (the “PIPE Warrants”).

On May 9, 2023, pursuant to the DCA, NextPlat received 570,599 shares, Charles M. Fernandez received 228,240 shares, and Rodney Barreto received 228,240 shares. To induce the approval of the debt conversion pursuant to the DCA, Messrs. Fernandez and Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. In addition, NextPlat and Messrs. Fernandez and Barreto also received a common stock purchase warrant to purchase one share of Common Stock for each share of Common Stock they received upon conversion of the Note.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and notes thereto included under Part I, Item I of this Quarterly Report on Form 10-Q. In addition, reference should be made to our audited Consolidated Financial Statements and notes thereto and related "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our 2022 Form 10-K. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs, including potential impacts on our business, results of operations and financial condition. Our actual results may differ materially from those contained in or implied by any forward-looking statements. The financial information included in this discussion and in our consolidated financial statements may not be indicative of our consolidated financial position, operating results, changes in equity and cash flows in the future. See "Special Note Regarding Forward-Looking Statements" included earlier in this report.

Note on Financial Presentation

In connection with the change in control on July 1, 2023, the application of push-down accounting created a new basis of accounting for all assets and liabilities based on their fair value at the date of acquisition. As a result, our financial position, results of operations, and cash flows subsequent to the acquisition on July 1, 2023 have been segregated to indicate pre-acquisition and post-acquisition periods. The pre-acquisition period through June 30, 2023 is referred to as the "Predecessor". The post-acquisition period, July 1, 2023 and forward, includes the impact of push-down accounting and is referred to as the "Successor". See "Note 4. Business Combination".

The information contained below should be read in conjunction with our historical condensed consolidated financial statements and the related notes.

Overview

Progressive Care Inc. was incorporated under the laws of the state of Delaware on October 31, 2006 under the name Progressive Training, Inc. We changed our name to Progressive Care Inc. in connection with a merger with Progressive Care Inc. on November 23, 2010. We are a personalized healthcare services and technology company which provides prescription pharmaceutical and risk and data management services to healthcare organizations and providers.

We currently own and operate five pharmacies, which generate most of our pharmacy revenues, which is derived from dispensing medications to our patients. We also provide patient health risk reviews and free same-day delivery.

We provide TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management. We are focused on improving the lives of patients with complex chronic diseases through a patient and provider engagement and our partnerships with payors, pharmaceutical manufacturers, and distributors. We offer a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Pharmco provides contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program. Under the terms of these agreements, we act as a pass-through for reimbursements on prescription claims adjudicated on behalf of the 340B covered entities in exchange for a dispensing fee per prescription. These fees vary by the covered entity and the level of service provided by us.

Our focus is on complex chronic diseases that generally require multiyear or lifelong therapy, which drives recurring revenue and sustainable growth. Our pharmacy services revenue growth is from expanding our services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers due to our focus on higher patient engagement, benefit of free delivery to the patient, and clinical expertise. We also expanded revenue growth through the signing of new contract pharmacy service and data management contracts with 340B covered entities.

ClearMetrX includes data management and TPA services for 340B covered entities, pharmacy analytics, and programs to manage HEDIS Quality Measures including Medication Adherence. These offerings cater to the need for frontline providers to understand best practices, patient behaviors, care management processes, and the financial mechanisms behind these decisions. We provide data access, and actionable insights that providers and support organizations can use to improve their practice and patient care. The Company's TPA services include management of wholesale accounts, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Our 340MetrX platform provides 340B covered entities with data insights to effectively operate and maximize the benefits of the 340B program. The platform allows program administrators to manage, in real time, data related to revenue, virtual inventory, drug replenishment and reconciliation, detailed prescription history analysis, customized ordering data with major wholesalers, patient information, drug prescribing trends, and customized financial breakdowns. The 340MetrX software enhances services currently provided to 340B covered entities by complementing in-house 340B experts with a reporting platform aiming to maximize the limited resources in the 340B space through identification and validation of claims. 340MetrX allows our data analytics processes to be more efficient, giving our team the ability to seamlessly manage data for a much greater number of 340B covered entities in Florida, with potential to be scaled nationwide.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation included in our 2022 Form 10-K. The most recently adopted accounting pronouncements and accounting pronouncements to be adopted by the Company are described in Note 3 in the Notes to our Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

Results of Operations

Our results of operations as reported in our condensed consolidated financial statements for the periods three months ended September 30, 2023 (“Successor”), six months ended June 30, 2023 (“Predecessor”), and the three and nine months ended September 30, 2022 (“Predecessor”) are in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Although GAAP requires that we report on our results for the Successor and Predecessor periods separately, management views our operating results for the combined nine months ended September 30, 2023 by combining the results of the Predecessor and Successor periods because management believes such presentation provides the most meaningful comparison of our results to prior periods. We believe the key performance indicators such as operating revenues and expenses for the Successor period combined with the Predecessor period provide more meaningful comparisons to other periods and are useful in understanding operational trends. Additionally, there were no impacts as a result of push-down accounting on our results of operations. The information presented below for the six months ended June 30, 2023 should be read in conjunction with our second quarter 2023 Form 10-Q.

Three months ended September 30, 2023 compared to the three months ended September 30, 2022

The following table summarizes our results of operations:

	Successor	Predecessor		
	Three Months Ended September 30, 2023	Three Months Ended September 30, 2022	\$ Change	% Change
Total revenues, net	\$ 12,359,450	\$ 10,143,881	\$ 2,215,569	22%
Total cost of revenue	8,578,887	7,981,796	597,091	7%
Total gross profit	3,780,563	2,162,085	1,618,478	75%
Operating expenses	5,138,633	4,040,152	1,098,481	27%
Loss from operations	(1,358,070)	(1,878,067)	519,997	(28)%
Other loss	(16,678)	(7,084,561)	7,067,883	(100)%
Net loss attributable to common shareholders	\$ (1,374,748)	\$ (8,962,628)	\$ 7,587,880	(85)%

We recognized overall revenue from operations of approximately \$12.4 million and \$10.1 million during the three months ended September 30, 2023 and 2022, respectively, an overall increase of approximately \$2.2 million, or 22%. The increase in revenue was primarily attributable to an increase in prescription revenue, net of PBM fees of approximately \$1.1 million and an increase in 340B contract revenue of approximately \$1.3 million, which was offset by a decrease in COVID-19 testing revenue of approximately \$0.2 million, when compared to the prior year period.

Gross profit margins increased from 21% for the three months ended September 30, 2022, to 31% for the three months ended September 30, 2023. The increase in gross profit margins during the third quarter of 2023 compared to the same period in 2022, was primarily attributable to the increase in 340B contract revenue, which has higher margins than revenue generated from pharmacy operations.

Loss from operations decreased by approximately \$0.5 million for the three months ended September 30, 2023, when compared to the three months ended September 30, 2022, as a result of the increase in gross profit of approximately \$1.6 million, partially offset by the increase in operating expenses of approximately \$1.1 million.

Revenue

Our revenues were as follows:

	Successor		Predecessor			
	Three Months Ended September 30, 2023		Three Months Ended September 30, 2022		\$ Change	% Change
	Dollars	% of Revenue	Dollars	% of Revenue		
Sales of products, net						
Prescription revenue, net of PBM fees	\$ 9,872,908	80%	\$ 8,753,591	86%	\$ 1,119,317	13%
COVID-19 testing revenue	5,943	—%	235,221	—%	(229,278)	(97)%
Other revenue	9,039	—%	903	—%	8,136	901%
Subtotal	9,887,890	80%	8,989,715	89%	898,175	10%
Revenues from services:						
340B contract revenue	2,471,560	20%	1,154,166	11%	1,317,394	114%
Revenues, net	\$ 12,359,450	100%	\$ 10,143,881	100%	\$ 2,215,569	22%

We have filled approximately 122,000 and 117,000 prescriptions during the three months ended September 30, 2023 and 2022, respectively.

Dispensing fees and TPA revenue earned on our 340B contracts for the three months ended September 30, 2023 and 2022 were approximately \$2.5 million and \$1.2 million, respectively, an increase of approximately \$1.3 million. The increase in 340B contract revenue was attributable to an increase in our existing 340B contracts.

COVID-19 testing revenue decreased by approximately \$0.3 million for the three months ended September 30, 2023 when compared to the prior year period. Since the first quarter of 2022, the demand for COVID-19 testing decreased as the need for testing has decreased as it relates to travel and business continuity. It is difficult to predict whether these conditions will be recurring given the recent COVID-19 pandemic conditions in Florida. We are well positioned to react if another COVID-19 outbreak occurs as we have built a reputation of being a reliable partner for COVID-19 testing solutions. We have built reputable relationships with well-known media productions companies and these relationships may provide us with recurring COVID-19 testing revenue.

Operating Expenses

Our operating expenses increased by approximately \$1.1 million, or 27%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase was primarily attributable to increases of approximately \$0.6 million in the amortization of newly identifiable intangible assets as a result of the push-down accounting, approximately \$0.3 million of increased franchise taxes, and approximately \$0.2 million in salaries and wages, when compared to

the prior year period.

Other Loss

Other loss decreased by approximately \$7.1 million for the three months ended September 30, 2023, as compared to the same period in 2022. Other loss of approximately \$7.1 million in the prior year period was attributable to NextPlat transaction-related expenses and losses, including the changes in fair value of derivative liabilities, day one losses on issuance of units and debt modification, and abandoned offering costs, offset by gains on debt settlement and grant revenue.

Net Loss

We had a net loss of approximately \$1.4 million and \$9.0 million for the three months ended September 30, 2023 and 2022, respectively. The decrease in net loss was attributable to the decrease in other loss due to the NextPlat transaction-related expenses and losses recognized in the prior year period.

Nine months ended September 30, 2023 compared to the nine months ended September 30, 2022

The following table summarizes our results of operations:

	<u>Successor</u> Three Months Ended September 30,	<u>Predecessor</u>		<u>Predecessor</u> Nine Months Ended September 30,	<u>\$ Change</u>	<u>% Change</u>
	2023	Six Months Ended June 30, 2023	Nine Months Ended September 30, 2023	2022		
Total revenues, net	\$ 12,359,450	\$ 22,948,029	\$ 35,307,479	\$ 30,168,460	\$ 5,139,019	17%
Total cost of revenue	8,578,887	16,242,498	24,821,385	23,595,416	1,225,969	5%
Total gross profit	3,780,563	6,705,531	10,486,094	6,573,044	3,913,050	60%
Operating expenses	5,138,633	6,067,564	11,206,197	8,783,937	2,422,260	28%
(Loss) income from operations	(1,358,070)	637,967	(720,103)	(2,210,893)	1,490,790	(67)%
Other loss	(16,678)	(5,405,332)	(5,422,010)	(8,993,066)	3,571,056	(40)%
Loss before income taxes	(1,374,748)	(4,767,365)	(6,142,113)	(11,203,959)	5,061,846	(45)%
Income taxes	—	—	—	(866)	866	(100)%
Net loss attributable to common shareholders	\$ (1,374,748)	\$ (4,767,365)	\$ (6,142,113)	\$ (11,204,825)	\$ 5,062,712	(45)%

We recognized overall revenue from operations of approximately \$35.3 million and \$30.2 million during the nine months ended September 30, 2023 and 2022, respectively, an overall increase of approximately \$5.1 million, or 17%. The increase in revenue was primarily attributable to an increase in prescription revenue, net of PBM fees of approximately \$3.1 million and an increase in 340B contract revenue of approximately \$3.9 million, which was offset by a decrease in COVID-19 testing revenue of approximately \$1.8 million, when compared to the prior year period.

Gross profit margins increased from 22% for the nine months ended September 30, 2022, to 30% for the nine months ended September 30, 2023. The increase in gross profit margins during 2023, compared to the prior year, was primarily attributable to the increase in 340B contract revenue, which has higher margins than revenue generated from pharmacy operations.

Loss from operations decreased by approximately \$1.5 million for the nine months ended September 30, 2023, when compared to the nine months ended September 30, 2022, as a result of the increase in gross profit of approximately \$3.9 million, partially offset by the increase in operating expenses of approximately \$2.4 million.

Revenue

Our revenues were as follows:

	<u>Successor</u> Three Months Ended September 30,	<u>Predecessor</u>		<u>Predecessor</u>			
	2023	Six Months Ended June 30, 2023	Nine Months Ended September 30, 2023	Nine Months Ended September 30, 2022		<u>\$ Change</u>	<u>% Change</u>
	<u>Dollars</u>	<u>Dollars</u>	<u>Dollars</u>	<u>% of Revenue</u>	<u>Dollars</u>	<u>% of Revenue</u>	
Sales of products, net							
Prescription revenue, net of PBM fees	\$ 9,872,908	\$ 19,218,508	\$ 29,091,416	82%	\$ 26,023,243	86%	\$ 3,068,173 12%
COVID-19 testing revenue	5,943	53,603	59,546	—%	1,894,434	6%	(1,834,888) (97)%
Other revenue	9,039	5,703	14,742	—%	2,560	—%	12,182 476%
Subtotal	9,887,890	19,277,814	29,165,704	83%	27,920,237	93%	1,245,467 4%
Revenues from services:							
340B contract revenue	2,471,560	3,670,215	6,141,775	17%	2,248,223	7%	3,893,552 173%
Revenues, net	\$ 12,359,450	\$ 22,948,029	\$ 35,307,479	100%	\$ 30,168,460	100%	\$ 5,139,019 17%

We have filled approximately 360,000 and 346,000 prescriptions during the nine months ended September 30, 2023 and 2022, respectively, a 4% year-over-year increase.

Dispensing fees and TPA revenue earned on our 340B contracts for the nine months ended September 30, 2023 and 2022 were approximately \$6.1 million and \$2.2 million, respectively, an increase of approximately \$3.9 million. The increase in 340B contract revenue was attributable to an increase in our existing 340B contracts.

COVID-19 testing revenue decreased by approximately \$1.8 million for the nine months ended September 30, 2023 when compared to the prior year period due to the Company recording record COVID-19 testing revenue in the first quarter of 2022 as the country was dealing with the Delta and Omicron outbreak during that period. Since the first quarter of 2022, the demand for COVID-19 testing decreased as the need for testing has decreased as it relates to travel and business continuity. It is difficult to predict whether these conditions will be recurring given the recent COVID-19 pandemic conditions in Florida. We are well positioned to react if another COVID-19 outbreak occurs as we have built a reputation of being a reliable partner for COVID-19 testing solutions. We have built reputable relationships with well-known media productions companies and these relationships may provide us with recurring COVID-19 testing revenue.

Operating Expenses

Our operating expenses increased by approximately \$2.4 million, or 28%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily attributable to increases of approximately \$1.2 million in salaries and wages, \$0.6 million in the amortization of newly identifiable intangible assets as a result of the push-down accounting, \$0.3 million related to a settlement of a pharmacy claims audit in the ordinary course of business, and \$0.3 million in franchise taxes.

Other Loss

Other loss decreased by approximately \$3.6 million for the nine months ended September 30, 2023, as compared to the same period in 2022. Other loss of approximately \$5.4 million in 2023 was attributable to the debt conversion expense of approximately \$5.2 million. Other loss of approximately \$9.0 million in 2022 was attributable to the NextPlat transaction-related expenses and losses, including the changes in fair value of derivative liabilities, day one losses on issuance of units and debt modification, and abandoned offering costs, offset by gains on debt settlement and grant revenue.

Net Loss

We had a net loss of approximately \$6.1 million and \$11.2 million for the nine months ended September 30, 2023 and 2022, respectively. The decrease in net loss was attributable to the decrease in other loss due to the NextPlat transaction-related expenses and losses recognized in the prior year period.

Non-GAAP Financial Measures

We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, stock-based compensation, and certain other items that we do not consider indicative of our ongoing operating performance (which items are itemized below). Adjusted EBITDA is a non-GAAP financial measure.

We consider Adjusted EBITDA to be a supplemental measure of our operating performance. We present Adjusted EBITDA because it is used by our Board of Directors and management to evaluate our operating performance. It is also used as a factor in determining incentive compensation, for budgetary planning and forecasting overall financial and operational expectations, for identifying underlying trends, and for evaluating the effectiveness of our business strategies. Further, we believe it assists us, as well as investors, in comparing performance from period to period on a consistent basis. Adjusted EBITDA is not in accordance with, or an alternative to, measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles.

As a non-GAAP measure, Adjusted EBITDA has limitations in that it does not reflect all the amounts associated with our results of operations as determined in accordance with U.S. GAAP and therefore you should not consider Adjusted EBITDA in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP. You should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in the presentation, and we do not infer that our future results will be unaffected by unusual or non-recurring items. Adjusted EBITDA does not include:

- depreciation expense from property and equipment or amortization expense from intangible assets (and although they are non-cash charges, the assets being depreciated/amortized will often have to be replaced in the future);
- interest expense on our debt and capital leases or interest income we earn on cash;
- the amounts we paid in taxes or other components of our tax provision (which reduces cash available to us);
- change in fair value of derivatives;
- certain expenses associated with our acquisition activities; or
- the impact of stock-based compensation or other matters we do not consider to be indicative of our ongoing operations.

Further, other companies in our industry may calculate Adjusted EBITDA differently than we do and these calculations may not be comparable to our Adjusted EBITDA metric. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss attributable to us and our financial results presented in accordance with U.S. GAAP.

The table below presents a reconciliation of the most directly comparable U.S. GAAP measure, net loss attributable to us, to Adjusted EBITDA for the periods indicated below:

	<u>Successor</u> <u>Three Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2023</u>	<u>Predecessor</u> <u>Three</u> <u>Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2022</u>
Net loss	\$ (1,374,748)	\$ (8,962,628)
Interest expense	38,266	107,893
Change in fair value of derivative liability	—	7,894,100
Depreciation and amortization expense	707,554	49,493
Consolidated adjusted EBITDA	<u>\$ (628,928)</u>	<u>\$ (911,142)</u>

	<u>Successor</u> <u>Three Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2023</u>	<u>Predecessor</u> <u>Six Months</u> <u>Ended June</u> <u>30,</u> <u>2023</u>	<u>Predecessor</u> <u>Nine Months</u> <u>Ended</u> <u>September 30,</u> <u>2023</u>	<u>Predecessor</u> <u>Nine Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2022</u>
Net loss	\$ (1,374,748)	\$ (4,767,365)	\$ (6,142,113)	\$ (11,204,825)
Interest expense	38,266	214,640	252,906	645,183
Change in fair value of derivative liability	—	—	—	9,067,500
Income tax expense	—	—	—	866
Depreciation and amortization expense	707,554	136,686	844,240	145,691
Debt conversion expense	—	5,205,609	5,205,609	—
Consolidated adjusted EBITDA	<u>\$ (628,928)</u>	<u>\$ 789,570</u>	<u>\$ 160,642</u>	<u>\$ (1,345,585)</u>

Liquidity and Capital Resources

Cash Flows

The following table summarizes our cash flows:

	<u>Successor</u>	<u>Predecessor</u>		<u>Predecessor</u>
	<u>Three Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2023</u>	<u>Six Months</u> <u>Ended June</u> <u>30,</u> <u>2023</u>	<u>Nine Months</u> <u>Ended</u> <u>September 30,</u> <u>2023</u>	<u>Nine Months</u> <u>Ended</u> <u>September</u> <u>30,</u> <u>2022</u>
Net change in cash from:				
Operating activities	\$ (259,828)	\$ 150,209	\$ (109,619)	\$ 999,188
Investing activities	(349,862)	(230,864)	(580,726)	(4,276)
Financing activities	272,478	689,962	962,439	4,940,557
Change in cash	(337,212)	609,307	272,095	5,935,469
Cash at end of period	\$ 7,014,971	\$ 7,352,183	\$ 7,014,971	\$ 7,347,577

Net cash used in operating activities totaled approximately \$0.1 million for the nine months ended September 30, 2023, compared to net cash provided by operating activities of approximately \$1.0 million for the same period in 2022. Operational cash flows decreased due to the reduced payment terms in our 340B contracts, an increase in accounts receivable related to 340B contracts, an increase in inventory, and the recognition of debt conversion expense, partially offset by the change in fair value of derivative liability recorded in the prior year period.

Net cash used in investing activities was approximately \$0.6 million and \$4,000 for the nine months ended September 30, 2023 and 2022, respectively. The cash outflow in 2023 was attributable to investment in our fleet. The cash outflow in 2022 was attributable to the proceeds from disposal of property and equipment, offset by payments made in developing internal use software.

Net cash provided by financing activities was approximately \$1.0 million and \$4.9 million for the nine months ended September 30, 2023 and 2022, respectively. The cash inflow in 2023 was attributable to the \$0.9 million net cash proceeds from the May 2023 PIPE transaction and \$0.5 million cash proceeds from warrants exercised, partially offset by payments made on notes payable. In September 2022, approximately \$5.4 million net proceeds were received from issuing preferred stock in a capital raise from NextPlat, which was offset by payments for debt discount and issuance costs as a result of debt modification of the Iliad Research note and entering into a new debt agreement with NextPlat Investors.

Liquidity and Capital Resources

We have an accumulated deficit of approximately \$21.1 million and \$15.0 million as of September 30, 2023 and December 31, 2022, respectively. We have spent, and expect to continue to spend, additional amounts in connection with implementing our business strategy.

For the nine months ended September 30, 2023, we had a net loss of approximately \$6.1 million and net cash used in operating activities of approximately \$0.1 million. The Company's cash position was approximately \$7.0 million as of September 30, 2023.

On May 5, 2023, we entered into a Securities Purchase Agreement (the "SPA") with NextPlat Corp ("NextPlat"), pursuant to which NextPlat agreed to purchase 455,000 newly issued units of securities from Progressive Care (the "Units") at a price per Unit of \$2.20 for an aggregate purchase price of \$1.0 million (the "Unit Purchase"). Each Unit consists of one share of common stock, par value \$0.0001 per share, of Progressive Care ("Common Stock") and one common stock purchase warrant to purchase a share of Common Stock (the "PIPE Warrants"). The PIPE Warrants have a three-year term and will be immediately exercisable. Each PIPE Warrant is exercisable at \$2.20 per share of Common Stock. On May 9, 2023, the Company and NextPlat closed the transactions contemplated in the SPA. We received cash proceeds of \$880,000, net of placement agent commission of \$70,000 and legal fees of \$50,000. We used the net proceeds from the Unit Purchase for our working capital needs.

At the same time, the Company and NextPlat entered into a First Amendment (the “Amendment”) to that certain Securities Purchase Agreement dated November 16, 2022 (the “Debtenture Purchase Agreement”). Under the Debtenture Purchase Agreement, we agreed to issue, and NextPlat agreed to purchase, from time to time during the three-year term of the Debtenture Purchase Agreement, up to an aggregate of \$10 million of secured convertible debtentures from NextPlat (the “Debtentures”). Pursuant to the Amendment, NextPlat and the Company agreed to amend the Debtenture Purchase Agreement and the form of Debtenture attached as an exhibit thereto to have a conversion price of \$2.20 per share. As of November 13, 2023, the date the Unaudited Condensed Consolidated Financial Statements were available to be issued, no Debtentures have been purchased by NextPlat under the Debtenture Purchase Agreement.

Management believes that the above transactions, along with our present cash position and the cash we expect to generate from pharmacy sales, will allow us to operate and meet our obligations over the next 12 months.

Off-Balance Sheet Arrangements

As of September 30, 2023, we had no material off-balance sheet arrangements or obligations that have or are reasonably likely to have a current or future effect on our financial condition, change in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Recent Accounting Pronouncements

The most recently adopted accounting pronouncements and accounting pronouncements to be adopted by the Company are described in Note 3 in the Notes to our Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, for this reporting period and are not required to provide the information required under this Item.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. In accordance with Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (“Exchange Act”) we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness and design of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our CEO and CFO have concluded that as of September 30, 2023 our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

(b) Inherent Limitations on Controls. Management, including the CEO and CFO, does not expect that our disclosure controls and procedures will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

(c) Changes in internal controls over financial reporting. There has been no change in our internal control over financial reporting during our fiscal quarter ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See “Note 16. Commitments and Contingencies – Legal Matters” included in the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

ITEM 1A. RISK FACTORS

Investors should carefully consider the risks in the “Risk Factors” in Part 1: Item 1A of our 2022 Form 10-K, and our other filings with the SEC. These risks are not the only ones facing the Company. Additional risks not currently known to us or that we currently believe are immaterial may also impair our business operations. Any of these risks could adversely affect our business, cash flows, financial condition, and results of operations. The trading price of our common stock could fluctuate due to any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q. Except as described below, there have been no material changes in our risk factors from those discussed in our 2022 Form 10-K.

As a result of the Voting Agreement entered into among NextPlat Corp., Charles M. Fernandez and Rodney Barreto, with respect to a majority voting interest in the Company’s common stock, your ability to influence corporate matters is expected to be limited.

Pursuant to the Voting Agreement dated June 30, 2023, Charles M. Fernandez, the Company’s Chairman and Chief Executive Officer, and Rodney Barreto, Vice-Chairman of the Company’s Board, agreed to vote all shares of common stock of the Company owned directly or indirectly and all future acquired shares, together with the vote of NextPlat Corp. at any annual meeting or special meeting of the Company’s shareholders, or any action by written consent. As of the date the financial statements were issued, NextPlat Corp., Messrs. Fernandez and Barreto beneficially own 3,203,520, 469,335, and 403,436 voting shares of common stock of the Company, respectively, comprising collectively approximately 53% of the Company’s voting common stock. This concentration of ownership is also likely to have the effect of delaying or preventing a change of control of the Company, which other stockholders may view as beneficial.

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

On July 1, 2023, NextPlat Corp exercised common stock purchase warrants, pursuant to a Securities Purchase Agreement and Debt Conversion Agreement, on a cash basis and the Company issued 230,000 shares of common stock. The Company received \$506,000 and used the proceeds for working capital.

On July 1, 2023, NextPlat Corp exercised common stock purchase warrants, pursuant to a Securities Purchase Agreement and Debt Conversion Agreement, on a cashless basis and the Company issued 402,269 shares of common stock.

On July 1, 2023, Charles M. Fernandez exercised common stock purchase warrants, pursuant to a Securities Purchase Agreement and Debt Conversion Agreement, on a cashless basis and the Company issued 211,470 shares of common stock.

On July 1, 2023, Rodney Barreto exercised common stock purchase warrants, pursuant to a Securities Purchase Agreement and Debt Conversion Agreement, on a cashless basis and the Company issued 130,571 shares of common stock.

During the three months ended September 30, 2023, there were no repurchases of our common stock.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Arrangement

During the three months ended September 30, 2023, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6. EXHIBITS

- 10.1 [Voting Agreement by and between NextPlat Corp., Charles M. Fernandez, and Rodney Barreto, dated June 30, 2023.](#)
- 31.1 [Certification of Chairman and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#)
- 31.2 [Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#)
- 32.1 [Certification of Chairman and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](#)
- 32.2 [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](#)
- 101.INS XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
- 101 The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
- 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Progressive Care Inc.

Date: November 13, 2023

By: /s/ Charles M. Fernandez

Charles M. Fernandez
Chief Executive Officer
(Principal Executive Officer)

Date: November 13, 2023

By: /s/ Cecile Munnik

Cecile Munnik
Chief Financial Officer
(Principal Financial and Accounting Officer)

VOTING AGREEMENT

THIS VOTING AGREEMENT (this “**Agreement**”) is made and entered into as of June 30, 2023, by and between NextPlat Corp, a Nevada corporation (the “**NextPlat**”), Charles M. Fernandez (“**Mr. Fernandez**”), and Rodney Barreto (“**Mr. Barreto**”). Each of NextPlat, Mr. Fernandez and Mr. Barreto is individually referred to herein as a “**Party**” and together as the “**Parties**”.

RECITALS

- A. NextPlat, Mr. Fernandez and Mr. Barreto each directly or indirectly own common stock and certain other securities convertible into common stock issued by Progressive Care Inc., a Delaware company (“**Progressive**”).
- B. The Parties desire to facilitate the voting arrangement set forth in this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the promises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Voting. At any annual or special shareholders meeting of the stockholders of Progressive, and whenever the holders of the Progressive’s common stock (“**Common Stock**”) act by written consent, Messrs. Fernandez and Barreto hereby agree to vote all of the shares of Common Stock (including any new shares hereafter acquired or acquired through the conversion of securities convertible into Common Stock) that they own, directly or indirectly, in the same manner that NextPlat votes its Common Stock and equivalents.

2. Term. The term of this Agreement is perpetual but may be terminated by either party, for or without cause, upon sixty (60) days’ written notice to the other party.

3. Miscellaneous.

(a) Specific Performance. The Parties hereby declare that it is impossible to measure in money the damages which will accrue to a Party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement will be specifically enforceable. If any party hereto or his heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person will not offer in any such action or proceeding the claim or defense that such remedy at law exists.

(b) Governing Law. This Agreement, and the rights of the parties hereto, will be governed by and construed in accordance with the laws of the State of Delaware as such laws apply to agreements among Delaware residents made and to be performed entirely within the State of Delaware.

(c) Amendment or Waiver. This Agreement may be amended (or provisions of this Agreement waived) only by an instrument in writing signed by the Party against whom enforcement is sought. Any amendment or waiver so effected will be binding upon such Party and any assignee of any such Party.

(d) Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

(e) Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective heirs, successors, assigns, administrators, executors and other legal representatives.

(f) Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same agreement.

(g) Waiver. Except as set forth in Section 3(c), no waivers of any breach of this Agreement extended by any Party hereto to any other party will be construed as a waiver of any rights or remedies of any other Party hereto or with respect to any subsequent breach.

(h) Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the Parties with regard to the subjects hereof and no Party will be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein.

[REMAINDER OF PAGE INTENTIONALLY BLANK]

IN WITNESS WHEREOF, the parties hereto have executed this VOTING AGREEMENT as of the date first above written.

NEXTPLAT CORP

By: _____
Name:
Title

Charles M. Fernandez

Rodney Barreto

PROGRESSIVE CARE INC.
CERTIFICATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Charles M. Fernandez, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2023, of Progressive Care Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including the registrant's consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2023

/s/ Charles M. Fernandez

Charles M. Fernandez
Chairman and Chief Executive Officer
(Principal Executive Officer)

PROGRESSIVE CARE INC.
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Cecile Munnik, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2023, of Progressive Care Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including the registrant's consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2023

/s/ Cecile Munnik

Cecile Munnik

Chief Financial Officer

(Principal Financial and Accounting Officer)

**PROGRESSIVE CARE INC.
CERTIFICATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Progressive Care Inc. (“Progressive Care”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles M. Fernandez, Chairman and Chief Executive Officer of Progressive Care Inc., certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2023

/s/ Charles M. Fernandez

Charles M. Fernandez
Chairman and Chief Executive Officer
(Principal Executive Officer)

**PROGRESSIVE CARE INC.
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Progressive Care Inc. (“Progressive Care”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecile Munnik, Chief Financial Officer of Progressive Care Inc., certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2023

/s/ Cecile Munnik

Cecile Munnik

Chief Financial Officer

(Principal Financial and Accounting Officer)